ResMed (NYSE:RMD) reported better-than-expected third-quarter financial results on Thursday. ResMed posted adjusted earnings of $2.13 per share, beating market expectations of $1.91 per share. The company's quarterly sales came in at $1.200 billion versus estimates of $1.167 billion, according to data from Benzinga Pro. Gross margin rose 260 bps to 57.9%, while non-GAAP gross margin increased 240 bps to 58.5%. “ResMed’s strong third-quarter fiscal year 2024 results reflect robust patient and customer demand for our products and software solutions, leading to ...